ArticleScientific reports2026
Mechanism of matrine inhibiting retinoblastoma cell growth by downregulating NR1D2 to regulate phosphorylation of the PI3K/AKT signaling pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explored the mechanism of matrine-induced apoptosis in human retinoblastoma (RB) cell. Network pharmacology and proteomics approaches were employed to screen the intersection between the pharmacodynamic targets of matrine and the pathogenic targets of RB, and to identify the key signaling pathways underlying the anti-RB effect of matrine. Cytological experiments were used to evaluate cell proliferation, apoptosis, and the expression of PI3K/AKT pathway and apoptosis-related proteins. Results showed matrine inhibited Y79 and WERI-Rb-1 cell growth time- and dose-dependently, suppressed migration, and induced apoptosis. Integrated omics analysis identified Nuclear Receptor Subfamily 1 Group D Member 2 (NR1D2) as a primary responsive target. Matrine markedly downregulated NR1D2 expression at both the mRNA and protein levels. Matrine treatment and NR1D2 interference significantly promoted apoptosis (P < 0.05), while NR1D2 overexpression antagonized the pro-apoptotic effect of matrine. Total PI3K and AKT levels were unchanged, but their phosphorylated forms were altered; matrine-induced apoptosis correlated with Bax, Cleaved Caspase-3 upregulation and Bcl-2 downregulation. Thus, matrine inhibits RB Y79 cell growth by downregulating NR1D2, inhibiting PI3K/AKT phosphorylation and inducing RB cell apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.